Patents by Inventor Hiroki Wada

Hiroki Wada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8895570
    Abstract: The invention provides the compound of formula (I) and pharmaceutically acceptable salt thereof, pharmaceutical compositions containing the compound and the use of the compound in therapy.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: November 25, 2014
    Assignee: AstraZeneca AB
    Inventors: Phillip Abbott, Roger Victor Bonnert, Thomas McInally, Stephen Thom, Hiroki Wada, Satoshi Onuma
  • Publication number: 20140045837
    Abstract: The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 13, 2014
    Applicants: AstraZeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Ayumu Kurimoto, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
  • Publication number: 20130338174
    Abstract: The invention provides the compound of formula (I) and pharmaceutically acceptable salt thereof, pharmaceutical compositions containing the compound and the use of the compound in therapy.
    Type: Application
    Filed: December 14, 2011
    Publication date: December 19, 2013
    Inventors: Phillip Abbott, Roger Victor Bonnert, Thomas Mcinally, Stephen Thom, Hiroki Wada, Satoshi Onuma
  • Publication number: 20130328583
    Abstract: A power-on self-test circuit and a pattern generation circuit are provided. The power-on self-test circuit includes a selection circuit and a comparator circuit. The selection circuit selects, instead of an external pin group corresponding to a test access port, an output of the pattern generation circuit when a self-diagnosis execution signal is asserted and supplies a test pattern generated by the pattern generation circuit to a built-in self-test circuit. The comparator circuit compares a test result of a circuit-under-test with an expected value. By asserting the self-diagnosis execution signal in this manner, the semiconductor integrated circuit mounted on a user system executes BIST.
    Type: Application
    Filed: June 6, 2013
    Publication date: December 12, 2013
    Inventors: Hiroki Wada, Yoichi Maeda
  • Patent number: 8575180
    Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: November 5, 2013
    Assignees: AstraZeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Ayumu Kurimoto, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
  • Publication number: 20130123275
    Abstract: The invention concerns pyrazine derivatives of the Formula I or pharmaceutically-acceptable salts thereof; wherein each of n, m and R has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of bone-related disorders or conditions.
    Type: Application
    Filed: May 7, 2012
    Publication date: May 16, 2013
    Applicant: ASTRAZENECA AB
    Inventors: Tao FENG, Hitesh Jayantilal SANGANEE, Hiroki WADA
  • Patent number: 8436178
    Abstract: The present invention provides compounds of formula (I) wherein Ra, R1, R2, R3, X1, Y1, Z1, A, n and m are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: May 7, 2013
    Assignees: AstraZeneca AB, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Roger Victor Bonnert, Thomas McInally, Stephen Thom, Hiroki Wada
  • Patent number: 8198285
    Abstract: The invention concerns pyrazine derivatives of the Formula I or pharmaceutically-acceptable salts thereof; wherein each of n, m and R has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of bone-related disorders or conditions.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: June 12, 2012
    Assignee: Astrazeneca AB
    Inventors: Tao Feng, Hitesh Jayantilal Sanganee, Hiroki Wada
  • Patent number: 8138172
    Abstract: The present invention provides 8-oxoadenine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The 8-oxoadenine derivatives act as modulators of Toll-like Receptor (TLR) 7 and thus may be used in the treatment of asthma, hepatitis, allergic diseases, viral and bacterial infection as well as cancer.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: March 20, 2012
    Assignees: AstraZeneca AB, Dainippon Sumitomo Pharma Co Ltd.
    Inventors: Anthony Cook, Tom McInally, Stephen Thom, Hiroki Wada
  • Publication number: 20120022082
    Abstract: The invention concerns pyrazine derivatives of the Formula I or pharmaceutically-acceptable salts thereof; wherein each of n, m and R has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of bone-related disorders or conditions.
    Type: Application
    Filed: January 18, 2011
    Publication date: January 26, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Tao FENG, Hitesh Jayantilal SANGANEE, Hiroki WADA
  • Publication number: 20110306610
    Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Application
    Filed: July 20, 2011
    Publication date: December 15, 2011
    Applicants: AstraZeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Ayumu KURIMOTO, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
  • Patent number: 8012964
    Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: September 6, 2011
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., Astrazeneca Aktiebolag
    Inventors: Ayumu Kurimoto, Yoshiaki Isobe, Stephen Brough, Hiroki Wada, Roger Bonnert, Thomas McInally
  • Publication number: 20100280001
    Abstract: The present invention provides compounds of formula (I) wherein Ra, R1, R2, R3, X1, Y1, Z1, A, n and m are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: May 6, 2008
    Publication date: November 4, 2010
    Inventors: Roger Victor Bonnert, Thomas McInally, Stephen Thom, Hiroki Wada
  • Publication number: 20100240623
    Abstract: The present invention provides 8-oxoadenine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The 8-oxoadenine derivatives act as modulators of Toll-like Receptor (TLR) 7 and thus may be used in the treatment of asthma, hepatitis, allergic diseases, viral and bacterial infection as well as cancer.
    Type: Application
    Filed: July 3, 2007
    Publication date: September 23, 2010
    Inventors: Anthony Cook, Tom McInally, Stephen Thom, Hiroki Wada
  • Publication number: 20090143400
    Abstract: The present invention provides compounds of formula wherein n, Y, Z, R, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: September 12, 2006
    Publication date: June 4, 2009
    Inventors: Thomas McInally, Stephen Thom, Hiroki Wada
  • Publication number: 20080269240
    Abstract: An adenine compound useful as a medicine represented by the following formula (1): [wherein R1 is halogen atom, optionally substituted alkyl group, optionally substituted aryl group, etc.; X is oxygen atom, sulfur atom, a single bond, etc.; A1 is optionally substituted and optionally saturated 4 to 8 membered heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom, and 0 to 1 sulfur atom; A2 is optionally substituted 6 to 10 cyclic aromatic hydrocarbon group or optionally substituted 5 to 10 membered heterocyclic aromatic group; L1 and L2 are independently, substituted straight or branched alkylene or a single bond, etc.; L3 is optionally substituted straight or branched alkylene, etc.; R2 is hydrogen atom, optionally substituted alkyl group.] or its pharmaceutically acceptable salt.
    Type: Application
    Filed: September 21, 2006
    Publication date: October 30, 2008
    Applicants: Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan, AstraZeneca Aktiebolag A Corporation of Sweden
    Inventors: Kazuki Hashimoto, Tomoaki Nakamura, Kei Nakamura, Shingo Tojo, Ayumu Kurimoto, Yoshiaki Isobe, Hiroki Wada, Roger Bonnert
  • Publication number: 20070190071
    Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Application
    Filed: March 24, 2005
    Publication date: August 16, 2007
    Applicants: Dainippon Sumitomo Pharma Co., Ltd., AstraZeneca Aktiebolag
    Inventors: Ayumu Kurimoto, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
  • Patent number: 7227482
    Abstract: In a first-order complex band-pass filter, multiplexers are alternately switched over between time intervals of phases A and B, where the multiplexers includes two multiplexers provided at input and output stages, and a multiplexer provided in a feedback circuit of each of first-order filters and being switching over whether to invert a sign of a feedback signal. Then in a circuit part sandwiched between the multiplexers, a processing performed by an I circuit part and a processing performed by a Q circuit part are alternately switched over so that a sign of a signal inputted to an adder is inverted.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: June 5, 2007
    Assignee: Semiconductor Technology Academic Research Center
    Inventors: Hao San, Haruo Kobayashi, Hiroki Wada, Akira Hayakawa, Hiroyuki Hagiwara, Yoshitaka Jingu, Kazuyuki Kobayashi, Toshiro Tsukada
  • Publication number: 20060284751
    Abstract: In a first-order complex band-pass filter, multiplexers are alternately switched over between time intervals of phases A and B, where the multiplexers includes two multiplexers provided at input and output stages, and a multiplexer provided in a feedback circuit of each of first-order filters and being switching over whether to invert a sign of a feedback signal. Then in a circuit part sandwiched between the multiplexers, a processing performed by an I circuit part and a processing performed by a Q circuit part are alternately switched over so that a sign of a signal inputted to an adder is inverted.
    Type: Application
    Filed: April 24, 2006
    Publication date: December 21, 2006
    Applicant: Semiconductor Technology Academic Research Center
    Inventors: Hao San, Haruo Kobayashi, Hiroki Wada, Akira Hayakawa, Hiroyuki Hagiwara, Yoshitaka Jingu, Kazuyuki Kobayashi, Toshiro Tsukada
  • Patent number: D722642
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: February 17, 2015
    Assignee: Keyence Corporation
    Inventors: Hiroki Wada, Junji Ogawa